Celularity
CELU
66 hedge funds and large institutions have $98.9M invested in Celularity in 2022 Q2 according to their latest regulatory filings, with 39 funds opening new positions, 10 increasing their positions, 10 reducing their positions, and 11 closing their positions.
255% more first-time investments, than exits
New positions opened: 39 | Existing positions closed: 11
148% more call options, than puts
Call options by funds: $5.71M | Put options by funds: $2.31M
74% more funds holding
Funds holding: 38 → 66 (+28)
0.22% more ownership
Funds ownership: 1.95% → 2.17% (+0.22%)
0% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 10
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
57% less capital invested
Capital invested by funds: $232M → $98.9M (-$133M)
Top Buyers
| 1 |
AC
Armistice Capital
New York
|
+$15.2M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$14.7M |
| 3 |
BlackRock
New York
|
+$6.17M |
| 4 |
State Street
Boston,
Massachusetts
|
+$1.66M |
| 5 |
VIA
Vident Investment Advisory
Alpharetta,
Georgia
|
+$1.34M |
Top Sellers
| 1 |
PT
Palantir Technologies
Denver,
Colorado
|
-$5.92M |
| 2 |
Millennium Management
New York
|
-$2.85M |
| 3 |
HF
HRT Financial
New York
|
-$1.45M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$580K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$412K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
ARMC
76
American Research & Management Company
Marion,
Massachusetts
| – | +$487 | +6 | +120% |
|
77
Fidelity Investments
Boston,
Massachusetts
| – | +$569 | +7 | New |
|
CELU Hedge Fund Activity: Q2 2022 in Review
66 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Celularity (CELU) for Q2 2022, worth a combined $98.9M — down 57% from $232M a quarter earlier.
Buyers outnumbered sellers: 39 funds opened new CELU positions and 11 closed out — a net gain of 28 holders — while 10 added to existing stakes and 10 trimmed.
The largest buyer was Armistice Capital, opening a new position worth an estimated $15.2M. The largest seller was Palantir Technologies, cutting an estimated $5.92M.
- 66 institutional investors held Celularity (CELU) as of Q2 2022, up from 38 in Q1 2022.
- Funds reported $98.9M of Celularity stock for Q2 2022, down 57% quarter-over-quarter.
- 39 funds opened new Celularity positions in Q2 2022 and 11 closed out, a net change of +28 holders.
- The largest Celularity buyer in Q2 2022 was Armistice Capital, an estimated $15.2M added.
- The largest Celularity seller in Q2 2022 was Palantir Technologies, an estimated $5.92M sold.
Based on aggregated 13F filings for Q2 2022.